New version of India Tarceva purchasing agent 13621079267 India Tarceva price purchase

< .
-. 'r ', Ingredients
-. 'r ', Properties
Tablets: round, biconvex, white coated tablets, with gray printed on one side &r&, && and Tarceva logos, the other side is blank.
Tablets: round, biconvex, white coated tablets, with brown &r&, && and Tarceva logos printed on one side and blank on the other side.
-. 'r ', Indications
Erlotinib single agent is suitable for locally advanced or metastatic non-small cell lung cancer () after failure of at least one previous chemotherapy regimen.
In two multi-center, randomized, placebo-controlled phase III trials, the results showed that erlotinib combined with platinum-based chemotherapy regimens (carboplatin + paclitaxel or gemcitabine + cisplatin) can be used as first-line treatment for patients with locally advanced or metastatic disease. Treatment, compared with platinum-containing chemotherapy alone, does not increase clinical benefit, so it is not recommended for first-line treatment in the above conditions.
Erlotinib single agent can be used for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer who have stable disease after one cycle of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study (B) [see Clinical Trials]. No clinical study data are available comparing treatment with erlotinib in the absence of progression versus progression after first-line chemotherapy.